vs

Side-by-side financial comparison of Kimball Electronics, Inc. (KE) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Kimball Electronics, Inc. is the larger business by last-quarter revenue ($341.3M vs $197.9M, roughly 1.7× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs 1.1%, a 5.6% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs -4.5%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $-11.2M). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs -10.4%).

Kimball International, Inc. is an American company which consists of furniture brands: Kimball, National, Interwoven, Etc., David Edward, D'Style and Kimball Hospitality. It is the successor to W.W. Kimball and Company, the world's largest piano and organ manufacturer at certain times in the 19th and 20th centuries.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

KE vs RGEN — Head-to-Head

Bigger by revenue
KE
KE
1.7× larger
KE
$341.3M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+18.2% gap
RGEN
13.6%
-4.5%
KE
Higher net margin
RGEN
RGEN
5.6% more per $
RGEN
6.7%
1.1%
KE
More free cash flow
RGEN
RGEN
$28.8M more FCF
RGEN
$17.6M
$-11.2M
KE
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
-10.4%
KE

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
KE
KE
RGEN
RGEN
Revenue
$341.3M
$197.9M
Net Profit
$3.6M
$13.3M
Gross Margin
8.2%
52.5%
Operating Margin
3.2%
9.0%
Net Margin
1.1%
6.7%
Revenue YoY
-4.5%
13.6%
Net Profit YoY
6.0%
143.9%
EPS (diluted)
$0.15
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KE
KE
RGEN
RGEN
Q4 25
$341.3M
$197.9M
Q3 25
$365.6M
$188.8M
Q2 25
$380.5M
$182.4M
Q1 25
$374.6M
$169.2M
Q4 24
$357.4M
$174.1M
Q3 24
$374.3M
$154.9M
Q2 24
$430.2M
$154.1M
Q1 24
$425.0M
$151.3M
Net Profit
KE
KE
RGEN
RGEN
Q4 25
$3.6M
$13.3M
Q3 25
$10.1M
$14.9M
Q2 25
$6.6M
$14.9M
Q1 25
$3.8M
$5.8M
Q4 24
$3.4M
$-30.3M
Q3 24
$3.2M
$-654.0K
Q2 24
$7.5M
$3.3M
Q1 24
$-6.1M
$2.1M
Gross Margin
KE
KE
RGEN
RGEN
Q4 25
8.2%
52.5%
Q3 25
7.9%
53.2%
Q2 25
8.0%
50.0%
Q1 25
7.2%
53.6%
Q4 24
6.6%
26.1%
Q3 24
6.3%
50.0%
Q2 24
8.5%
49.8%
Q1 24
7.9%
49.5%
Operating Margin
KE
KE
RGEN
RGEN
Q4 25
3.2%
9.0%
Q3 25
4.0%
8.9%
Q2 25
4.3%
7.6%
Q1 25
3.1%
3.9%
Q4 24
2.3%
-17.7%
Q3 24
2.4%
-5.1%
Q2 24
4.6%
1.0%
Q1 24
-1.5%
1.3%
Net Margin
KE
KE
RGEN
RGEN
Q4 25
1.1%
6.7%
Q3 25
2.8%
7.9%
Q2 25
1.7%
8.2%
Q1 25
1.0%
3.4%
Q4 24
1.0%
-17.4%
Q3 24
0.8%
-0.4%
Q2 24
1.8%
2.2%
Q1 24
-1.4%
1.4%
EPS (diluted)
KE
KE
RGEN
RGEN
Q4 25
$0.15
$0.24
Q3 25
$0.40
$0.26
Q2 25
$0.27
$0.26
Q1 25
$0.15
$0.10
Q4 24
$0.14
$-0.55
Q3 24
$0.12
$-0.01
Q2 24
$0.29
$0.06
Q1 24
$-0.24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KE
KE
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$77.9M
$767.6M
Total DebtLower is stronger
$153.8M
$542.2M
Stockholders' EquityBook value
$579.2M
$2.1B
Total Assets
$1.1B
$2.9B
Debt / EquityLower = less leverage
0.27×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KE
KE
RGEN
RGEN
Q4 25
$77.9M
$767.6M
Q3 25
$75.7M
$748.7M
Q2 25
$88.8M
$708.9M
Q1 25
$51.4M
$697.2M
Q4 24
$53.9M
$757.4M
Q3 24
$76.6M
$784.0M
Q2 24
$78.0M
$809.1M
Q1 24
$65.2M
$780.6M
Total Debt
KE
KE
RGEN
RGEN
Q4 25
$153.8M
$542.2M
Q3 25
$137.5M
$537.9M
Q2 25
$147.1M
Q1 25
$178.3M
Q4 24
$204.5M
$525.6M
Q3 24
Q2 24
$294.8M
Q1 24
Stockholders' Equity
KE
KE
RGEN
RGEN
Q4 25
$579.2M
$2.1B
Q3 25
$577.1M
$2.1B
Q2 25
$569.9M
$2.1B
Q1 25
$548.1M
$2.0B
Q4 24
$537.5M
$2.0B
Q3 24
$547.8M
$2.0B
Q2 24
$540.5M
$2.0B
Q1 24
$539.1M
$2.0B
Total Assets
KE
KE
RGEN
RGEN
Q4 25
$1.1B
$2.9B
Q3 25
$1.1B
$2.9B
Q2 25
$1.1B
$2.9B
Q1 25
$1.1B
$2.9B
Q4 24
$1.1B
$2.8B
Q3 24
$1.1B
$2.8B
Q2 24
$1.2B
$2.9B
Q1 24
$1.3B
$2.8B
Debt / Equity
KE
KE
RGEN
RGEN
Q4 25
0.27×
0.26×
Q3 25
0.24×
0.26×
Q2 25
0.26×
Q1 25
0.33×
Q4 24
0.38×
0.27×
Q3 24
Q2 24
0.55×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KE
KE
RGEN
RGEN
Operating Cash FlowLast quarter
$6.9M
$25.7M
Free Cash FlowOCF − Capex
$-11.2M
$17.6M
FCF MarginFCF / Revenue
-3.3%
8.9%
Capex IntensityCapex / Revenue
5.3%
4.1%
Cash ConversionOCF / Net Profit
1.89×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$81.8M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KE
KE
RGEN
RGEN
Q4 25
$6.9M
$25.7M
Q3 25
$8.1M
$48.1M
Q2 25
$78.1M
$28.6M
Q1 25
$30.9M
$15.0M
Q4 24
$29.5M
$39.2M
Q3 24
$45.5M
$49.3M
Q2 24
$48.5M
$42.2M
Q1 24
$42.6M
$44.7M
Free Cash Flow
KE
KE
RGEN
RGEN
Q4 25
$-11.2M
$17.6M
Q3 25
$-2.5M
$43.4M
Q2 25
$68.4M
$21.5M
Q1 25
$27.0M
$11.4M
Q4 24
$23.1M
$33.6M
Q3 24
$32.1M
$42.3M
Q2 24
$39.5M
$37.4M
Q1 24
$30.0M
$36.4M
FCF Margin
KE
KE
RGEN
RGEN
Q4 25
-3.3%
8.9%
Q3 25
-0.7%
23.0%
Q2 25
18.0%
11.8%
Q1 25
7.2%
6.8%
Q4 24
6.5%
19.3%
Q3 24
8.6%
27.3%
Q2 24
9.2%
24.3%
Q1 24
7.1%
24.0%
Capex Intensity
KE
KE
RGEN
RGEN
Q4 25
5.3%
4.1%
Q3 25
2.9%
2.5%
Q2 25
2.5%
3.9%
Q1 25
1.0%
2.1%
Q4 24
1.8%
3.2%
Q3 24
3.6%
4.5%
Q2 24
2.1%
3.1%
Q1 24
3.0%
5.5%
Cash Conversion
KE
KE
RGEN
RGEN
Q4 25
1.89×
1.93×
Q3 25
0.80×
3.23×
Q2 25
11.86×
1.92×
Q1 25
8.11×
2.57×
Q4 24
8.58×
Q3 24
14.42×
Q2 24
6.43×
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KE
KE

Automotive$162.3M48%
Medical$96.3M28%
Industrial$82.7M24%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons